文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

DNA损伤应答基因研究验证DNA修复在儿童癌症风险中的作用并鉴定SMARCAL1为新的骨肉瘤易感基因

Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.
PubMed 文献 · J Clin Oncol · 2025-10-09

该研究系统分析189个DNA损伤修复基因在5,993例儿童癌症病例和14,477例成人非癌对照中的胚系致病变异,发现TP53等已知关联及BRCA1、SPIDR、SMC5和SMARCAL1四个新关联,其中SMARCAL1与骨肉瘤的关联在三个独立队列中均显著。结论确认DDR基因变异与儿童癌症风险相关,并将SMARCAL1确立为新的骨肉瘤易感基因。

要点

  • 儿童癌症中DNA修复基因胚系致病变异富集,SMARCAL1与骨肉瘤关联显著。
  • SMARCAL1:骨肉瘤关联在发现队列和三个复制队列中均得到验证。
  • 已知关联如TP53与肾上腺皮质癌、高级别胶质瘤和髓母细胞瘤等被确认。

核心结论

  • 本研究确认DDR基因变异与儿童癌症风险相关,并确立SMARCAL1为新的骨肉瘤易感基因。

研究设计与样本

  • 发现队列包括5,993例儿童癌症病例和14,477例成人非癌对照,对189个DDR基因进行胚系致病变异分析。
  • 使用分级方法结合ClinVar注释、InterVar分类及REVEL、CADD和MetaSVM等计算机工具判定致病变异。
  • 采用逻辑回归和Firth回归识别在儿童肿瘤胚系中统计富集的基因,并在三个独立队列共1,497例儿童癌症病例中复制。

主要发现

  • 所有癌症病例分析显示TP53致病变异富集。
  • 癌症特异性分析确认已知关联包括肾上腺皮质癌、高级别胶质瘤和髓母细胞瘤中的胚系TP53致病变异,高级别胶质瘤和非霍奇金淋巴瘤中的PMS2,高级别胶质瘤中的MLH1,非霍奇金淋巴瘤中的BRCA2,以及神经母细胞瘤中的BARD1。
  • 发现四个新关联:室管膜瘤中的BRCA1、高级别胶质瘤中的SPIDR、髓母细胞瘤中的SMC5和骨肉瘤中的SMARCAL1。
  • SMARCAL1:骨肉瘤关联在发现队列中显著(6/230,2.6%,FDR_logistic=0.0189),并在三个复制队列中均显著(Childhood Cancer Survivor Study:8/275,2.9%,P_Fisher<.0001;Cancer Predisposition Syndrome-German Childhood Cancer Registry:4/135,3%,P_Fisher=.002;Individualized Therapy for Relapsed Malignancies in Childhood:4/217,1.8%,P_Fisher=.012)。
  • 在有数据的四例骨肉瘤中,三例的剩余野生型SMARCAL1等位基因缺失。

关键数值与推荐

  • 儿童癌症中已知癌症易感基因的致病变异携带率为5%-18%。
  • SMARCAL1:骨肉瘤关联的发现队列FDR_logistic=0.0189,复制队列P_Fisher<.0001、.002和.012。

临床怎么用

  • 研究结果提示对骨肉瘤患儿可考虑SMARCAL1胚系检测,以识别易感个体并优化管理。
  • DDR基因胚系变异分析有助于儿童癌症风险分层和遗传咨询。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are frequently somatically altered in pediatric tumors, have not been systematically examined as a source of novel cancer-predisposing signals. METHODS: To address this gap, we interrogated 189 DDR genes for presence of germline predisposing variants (PV) among 5,993 childhood cancer cases and 14,477 adult noncancer controls (discovery cohort). PV were determined using a tiered approach incorporating ClinVar annotations, InterVar classification, and in silico tools (REVEL, CADD, and MetaSVM). Using logistic and firth regression, we identified genes with PV statistically enriched in the germline of children with tumors and replicated findings among 1,497 additional childhood cancer cases across three independent cohorts. RESULTS: Analysis across all cases with cancer revealed enrichment of TP53 PV. Cancer-specific analyses confirmed known associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and medulloblastoma (MB), PMS2 in HGG and non-Hodgkin lymphoma (NHL), MLH1 in HGG, BRCA2 in NHL, and BARD1 in neuroblastoma. In addition, four novel associations were uncovered, including BRCA1 in ependymoma, SPIDR in HGG, SMC5 in MB, and SMARCAL1 in osteosarcoma (OS). Importantly, the SMARCAL1:OS association was significant in the discovery (6/230, 2.6%, false discovery rate [FDR]logistic = 0.0189) as well as all three replication cohorts (Childhood Cancer Survivor Study: 8/275, 2.9%; PFisher < .0001; Cancer Predisposition Syndrome-German Childhood Cancer Registry: 4/135, 3%, PFisher = .002; Individualized Therapy for Relapsed Malignancies in Childhood: 4/217, 1.8%, PFisher = .012). The remaining wild-type SMARCAL1 allele was deleted in three of four OS tumors with available data. CONCLUSION: Our study confirms the relevance DDR genetic variation in pediatric cancer risk and establishes SMARCAL1 as a novel OS predisposing gene, providing insights into tumor biology and creating opportunities to optimize care for patients with this challenging tumor.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oak N, Chen W, Blake A, et al. Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene. J Clin Oncol. 2025. PMID: 41066719. doi:10.1200/JCO-25-01114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。